Hematologic malignancies in patients with evaluation of serum levels and importance cyanocobalamin

Serum siyanokobolamin, folik asit ve ferritin düzeylerinin çeşitli hematolojik hastalıklarla ilişkili olduğunu bildiren çalışmalar mevcuttur. Biz de bu çalışmada çeşitli hematolojik malignite gruplarında ilk tanı anında serum siyanokobolamin, folik asit ve ferritin düzeylerini araştırmayı amaçladık. Gereç ve Yöntem. Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi Hematoloji poliklinik ve kliniğine 2010-2014 yılları arasında başvurmuş olan 18-75 yaş arası Akut Lenfoblastik lösemi (ALL), Akut Myeloblastik Lösemi (AML), Kronik Lenfositik Lösemi (KLL), Kronik Myelositik Lösemi (KML), Hodgkin Lenfoma (HL), Non-Hodgkin Lenfoma (NHL), Multiple Myelom (MM), Miyelodisplastik Sendrom (MDS) ve Polisitemia Vera (PV) tanılı 200 hasta çalışma kapsamına alındı. Çalışma kapsamına dahil edilen hastaların demografik, klinik ve laboratuar verileri hastane otomasyon sisteminden retrospektif olarak taranarak elde edilmiştir. Bulgular.Hastaların tanılarına göre dağılımı şu şekildedir: 13 hastada ALL (%5,6); 26 hastada AML (%11,3), 20 hastada HL (%8,7), 30 hastada KLL (%13), 20 hastada KML (%8,7), 16 hastada MDS (%6,9), 16 hastada MM (%6,9), 43 hastada NHL (%18,6) ve 17 hastada PV (%7,3) olduğu görüldü. Hastaların yaş ortalaması 56,315,8 yıl ve Vitamin B12 değerleri 344,9±279,0 pg/mL idi. Tanılar arasında Vitamin B12 değerlerinin anlamlı fark gösterdiği (p<0,001) tespit edildi. Hematolojik maligniteleri olan hasta grubunun ortanca genel sağ kalımları 60 ay (SH: 17,4 ay; %95 GA: 25,9-94,0 ay) idi. 1 yıllık genel sağ kalım oranları %71,8, 2 yıllık genel sağ kalım oranları %64,3, 3 yıllık genel sağ kalım oranları %55,1ve 5 yıllık genel sağ kalım oranları %48,9 idi. PV grubunda mortalite izlenmedi, en düşük ortanca genel sağ kalım 4 ay ile ALL grubunda idi (SH:1,8 ay; %95 GA: 0,5-7,5 ay), en uzun ortanca genel sağ kalım 79 ay ile KML grubunda idi (SH:17,6 ay; %95 GA: 44,4-113,6 ay). Sonuç. Hematolojik malignitesi olan hastalarda serum siyanokobalamin düzeyi yüksek bulunmuştur, bu yükseklik KML grubunda en belirgindir. Ortalama serum ferritin düzeyi hematolojik malignitelerde artarken, PV hastalarında düşük bulunmuştur. Vitamin B12, folat ve ferritinin çeşili hematolojik malignitelerdeki prognostik değerlerinin daha net olarak saptanması için daha geniş hasta sayılarını içeren, prospektif çalışmalara ihtiyaç vardır.Serum cyanocobalamin a my studies reporting that the folic acid and ferritin levels associated with various hematologic diseases. We also my first time of diagnosis serum cyanocobalamin various hematologic malignancies group in this study, we aimed to investigate folic acid and ferritin levels . Materials and Methods. Necmettin Erbakan University Meram Medical Faculty of Hematology policlinic and clinic to the years 2010-2014 between 18-75 years of age who have applied between acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia (AML), chronic lymphocytic leukemia (CLL) , chronic myelocytic leukemia (CML) Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), myelodysplastic syndrome (MDS) and polycythemia vera (PV), 200 patients were assessed in the study. Patients included in the study included demographic, clinical and laboratory data were obtained retrospectively from hospital automation system. Results. The distribution of patients according to the diagnosis are as follows: ALL 13 patients ( 5.6% ); 26 patients with AML ( 11.3%), 20 patients with HL (8.7%), CLL in 30 patients ( 13% ), CML in 20 patients ( 8.7 % ), 16 patients had MDS ( 6.9 %), 16 patients MM ( 6.9%) in 43 patients with NHL (18.6%) and 17 patients with PV (7.3%) was found to be. The average age of the patients was 56,315,8 year and vitamin B12 levels in 344.9 ± 279.0 pg / ml. Diagnosis showed significant differences between the vitamin B12 levels ( p <0.001) were observed. The median overall survival of 60 months, patients with hematologic malignancies (SHA : 17.4 months ; 95% CI : 25.9 to 94.0 months) . 1 -year overall survival rate of 71.8 %, 2 -year overall survival rate of 64.3 % , 3 -year overall survival rates of overall survival %55, 1 and 5 year overall survial rates were 48.9%. PV group no mortality was observed , was the lowest median overall survival ALL group with 4 months ( SE: 1.8 months ; 95% CI : 0.5 to 7.5 months), the longest median in the CML group with overall survival of 79 months id (SHA : 17.6 months ; 95% CI : 44.4 to 113.6 months). Conclusion. In patients with hematologic malignancies had elevated serum levels of cyanocobalamin , which is most noticeable in height KML group . The mean serum ferritin levels were increased in hematological malignancies were lower in PV patients. Vitamin B12, folate and ferritin containing larger numbers of patients to determine more clearly the prognostic value in hematologic malignancies, there is a need for prospective studie

Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Aim: To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. Methods: This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 mu g/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.' Results: The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio: 0.830; p = 0.043). Conclusion: More than half of cancer patients receiving active systemic therapy developed immunogenicity. Tweetable abstract Immunogenicity developed with CoronaVac in 25 (59.5%) of 42 patients who received at least one cytotoxic drug and in all patients (n = 5) who received monoclonal antibody or immunotherapy alone

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile

The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study

Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile

Major and minor salivary gland cancers: A multicenter retrospective study

Background: Most of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only including epidemiological data. Methods: A total of 37 medical oncology clinics from different regions of Turkey participated in this retrospective-multicenter study. The analyzed data included clinical and demographical features, primary treatment, metastasis localizations, and treatments and includes certain pathologic features. Results: The study included data from a total of 443 SGCs. 56.7% was in major salivary glands and 43.3% was in minor salivary glands. Distant metastasis in the major SGCs was statistically significantly more common than in the minor SGCs, locoregional recurrence was statistically significantly more common in the minor SGCs than in the major SGCs (p = 0.003). Conclusions: Epidemiological information, metastasis and recurrence patterns, treatment modalities, and survival analysis of the patients over 20 years of follow-up are presented